F anion. Labeling of 5 mg of precursor was performed in anhydrous acetonitrile at 100°C for 10 min, and the hydrolysis with HCl was performed at 100°C for 5 min. Final purifi cation was done with high-performance liquid chromatography (HPLC) and the radiochemical purity of radiotracer was higher than 99%. Proposed [ 18 F]FMISO synthesis was used as a reliable tool in studies on hypoxia in Lewis lung carcinoma (LLC) in mouse models.
Introduction
Hypoxia defi nes a pathological condition where oxygen is delivered to the tissue in insuffi cient quantities, which is the result of impaired oxygen transport mechanism. Hypoxic conditions may have the features of the pathological process, e.g. during the development of uncontrolled proliferative lesions [1, 2] . Regardless of the stage of the cancer, tumor hypoxia is considered to be unfavorable prognostic factor [3] . Hypoxic cells exhibit greater resistance to all therapeutic modes [4] and provide higher probability of metastasis and recurrence [5] . Therefore, the determination of the level and spatial distribution of hypoxia in tumor cells is an important diagnostic problem.
In recent years, the molecular imaging methods, in particular positron emission tomography (PET), proved the effectiveness in the diagnosis of hypoxic conditions.
As a radiopharmaceutical for the diagnosis of hypoxia, a complex of radioactive copper-64 (t 1/2 = 12.7 h) with a neutral lipophilic molecule ATSM (diacetyl-bis(N4-methylthiosemicarbazone)) was successfully applied [6] . 64 [10] , monitoring of anticancer treatments [11] , response evaluation [12] , and molecular backgrounds of spontaneous tumors [13] .
This paper describes an application of 
Materials and methods

Identifi cation and quality control
Identity of manufactured [
18 F]FMISO was confi rmed by comparison of retention time to the certifi ed reference standard (CRS) of main compound (ABX, Radeberg, Germany).
Radiochemical purity was performed with chromatography system Shimadzu AD20 with UV-Vis (ultraviolet-visible) and radiometric detector (GabiStar, Raytest, Germany). Twenty microliters Other identifi cation tests, half-life measurements, pH, residual solvents, and radionuclidic purity were performed as described earlier for [ 18 F]FDG [14] .
Animals and tumor model
LLC cells were grown at 37°C in a humidifi ed atmosphere of 5% CO 2 /95% air in RPMI 1640 containing 10% heat-inactivated fetal bovine serum plus penicillin-streptomycin under sterile tissue culture conditions. C57BL/6JOlaHsd, N = 10 female mice of 8-10 weeks of age and about 20 g of each were originally obtained from the animal breeding facility at the Faculty of Biochemistry, Biophysics and Biotechnology of the Jagiellonian University (Cracow, Poland). All the experimental procedures were approved by the First Local Ethic Committee of the Jagiellonian University (Permission Nos. 107/2013 and 91/2014). Mice were kept under constant conditions of 12/12 light cycle, humidity of 60%, and temperature of about 23°C. Standard laboratory diet with free access to drinking water were given in community cages. For each mouse, 0.5 × 10 6 LLC cells, suspended in 100 L of PBS, was injected intradermally into the right hind limb. The tumors became visible in 4-6 days after implantation. When their size (greatest diameter) were about 5 mm, mice were transported in cages specially prepared for this purpose to Biological and Chemical Research Centre of the University of Warsaw. Positron emission tomography-computed tomography (PET/ CT) measurements were performed after minimum 24 hours of acclimation after travel.
PET/CT measurements
Experiments were performed on Albira PET/ SPECT/CT Preclinical Imaging System (Bruker, Germany). Before measurements, mice were anesthetized with 2% isofl urane (Aerrane, Baxter Polska Sp. z o.o., Poland) in oxygen delivered through a nose cone and place on the heating pad. Thin cannula connected with a pressure equalizing (PE) tube (PE 50) of 15 cm long fi lled with saline was placed in tail vein. Prepared mice were placed in the supine position in the imager with the use of the animal bed, and 10-15 MBq [ 18 F]FMISO was administered i.v. through tail vein cannula. Isofl urane anesthesia were maintained through entire radiopharmaceutical uptake and image acquisition. Respiration was monitored with pressure pad connected to differential pressure transducers for low-range pressure monitoring (Biopac MP150 Acquisition System) during entire PET/CT examination and regulated by changing isofl urane concentration. PET scans were performed 120 min after injection. Emission data were collected for 1, 5, and 10 min. Spatial resolution of PET measurements was 1.1 mm. The scan parameters were set as follow: tube voltage was 45 kVp, tube current was 400 A, and number of projections was 400. Minimal resolution of CT was 90 m. The PET and CT images were fused using a PMOD software. Because the mouse remains in the same position on the bed for both PET and CT acquisitions, the software module can use the positional information to fuse and coregister the PET and CT data. After acidic hydrolysis, the solution was purifi ed with built-in HPLC on C18-RP (Phenomenex Gemini C18 250 mm × 10 mm × 7 m). This method of separation was confi rmed as the most effective purifi cation method [15] . To receive high specifi c activity, the modifi cation of synthesis module was done to enable the collection of the fraction with highest activity of fi nal product. The 1-mL portion of the most concentrated product at the output form HPLC column was cut-off by valve V27 and directly delivered with helium stream to the fi nal product vial, after passing through the 0.22-m sterile fi lter. Finally, it was formulated with saline (0.9% w/v) and dispensed in manual module DDS-A (Tema Sinergie, Italy).
Results and discussion
Synthesis
Radiochemical yield was 35.1 ± 1.2% (not corrected); total synthesis time including activity and fi nal product transfer was 50-52 min, which is comparable to recently published papers [15, 16] , taking into consideration yield dependency on initial precursor mass [17] . The labeling reaction was followed with preparative HPLC, ensuring good separation of fi nal product from impurities and the radiochemical purity >99%. On the basis of the starting activity of 4.0-6.0 GBq, 1.2-1.7 GBq of product with specifi c activity of 200-250 MBq/mL was obtained, which was suffi cient for the injection of several animals in standard imaging mode.
Quality control
18
F was identifi ed by recording the principal -peak at 511.5 ± 0.3 keV and determining the half-life (108.8 ± 0.3 min). The presence of any peaks with an energy different from 511 keV was checked and, except signals coming from Pb-X-rays (range 70-80 keV), none was found. That confi rmed a better than 99.9% radionuclidic purity. Then the sample was left for 24 h to decay and again impurities were tested with no signifi cant peaks, except residual activity of (Fig. 3) . Recorded retention times were 4.42 min for the standard and 4.65 min for the principal peak in radiochromatogram.
Radiochemical purity was determined by HPLC with radiometric detection, where the peak of [ (Fig. 3b) (Fig. 4) . The physiological uptake of glucose is located in the heart and bladder; in the case of [ [11] . In the stomach and intestine, high absorption was observed 30 min after the injection, whereas in the kidney, uptake increased 30 min after injection and remained in bladder at a high level to 120 min. 18 [F]FDG was preferentially taken up by metabolically active tumor regions. The reason for the differences in structure of imaged tumor depends on the uptake mechanism of the marker [18] , where the uptake of [ 
Conclusions
Synthesis of [
18 F]FMISO using 5 mg of precursor NITTP offered reliable manufacturing of good yield and high-purity radiopharmaceutical. The modifi cations to the synthesis unit allowed to receive suffi cient activity to perform PET experiments in animal subjects. Produced [
18 F]FMISO was used as a reliable tool in studies on hypoxia in LLC in mouse models.
